Simon Baker: Thank you for taking my questions. Two if I may. Firstly on China. Growth looks pretty good over there, but I just wondering if you could give us an update on the impact of reduced access to Chinese hospitals on how that is affecting things, if indeed at all. And then secondly on semaglutide, there was an interesting journal pre-print on Monday looking at its use in alcohol use disorder, which look very impressive. Be interesting to get your thoughts on the potential of that indication in your opinion. Thanks so much.
Daniel Bohsen: Thank you, Simon. So, Camilla, the first one to you. Do we see reduced access to Chinese hospitals?
Camilla Sylvest: So, in general, we are working across the country and we also have access to two hospitals. In general, what we do see in China is an effect of the VPP of course, that’s what you mean the insulin sales result, and that is also when you look at an overall IO business point of view that is what is actually dragging down the overall IO insulin growth, but in China Ozempic is going really well. We have a great momentum of Ozempic that we’ve had since the launch, and since the inclusion on the reimbursement list and that can drive growth in China.
Daniel Bohsen: No major issues with access. Martin, The second question.
Martin Holst Lange: Yes, thank you very much for the question. We’ve also seen these observational studies and been intrigued by the fact that GLP-1 may have a place in also treating alcohol abuse. That was actually live within the mode of action of GLP-1. From our perspective and also considering the timing, the combination of two mode of action that could potentially also help here, namely GLP-1 and Amylin. So specifically, from our perspective, sorry CagriSema is probably the more attractive and efficacious approach. So if you see us going into that space that would be with CagriSema and not with Semaglutide alone.
Daniel Bohsen: Thank you, Martin.
Simon Baker: Thanks so much.
Daniel Bohsen: We’re ready for the next question.
Operator: Thank you. Your next question comes from the line of Naresh Chouhan from Intron Health. Please go ahead.
Naresh Chouhan: Hi there. Thanks for taking my questions. First one, on Wegovy US market access. We are hearing that a growing number of employers are having to opt out having already opted in because the demand’s been too high. Can you just help us to get a sense of how big or small an issue this is? And obviously next year that’s probably potentially like to increase when supply resumes and demand increases. And secondly on supply, if I look back at when you seemed to relatively comfortable with the demand, we were at about 30,000 new PET starts a week in the US. Would that be — is that a fair starting point for kind of the ability to supply and growth from there going into 2024? Thank you.
Daniel Bohsen: Thank you Naresh. So Doug, any updates on the US market access for Wegovy.
Doug Langa: Yes, thanks, Naresh. Overall, we’re very pleased with the broad market access that we have for Wegovy. Most major PBMs and health plans are covering it that derives around 50 million people with obesity now been covered. And importantly, we’re seeing about 80% of the patients that are paying less than $25 for Wegovy. Now to your question, specifically around employers. We do see some opt-outs, but we are seeing overall more opt-ins, than opt-out. So directionally we’re heading in the right direction. And our focus, what could be continuing on securing employer coverage as well as stronger access for AOMs overall.
Daniel Bohsen: Thank you, Doug. Karsten, any additional comments on the supply going into next year?
Karsten Munk Knudsen: So I think the way to look at the suppliers is a starting point of currently around 100,000 TRx per week, according to IQVIA and then we have the five different dose strengths and of course the metric is to get that split right into the link into manufacturing and then we scale from there. And as we’ve said in prior quarters then this is something we do dynamically. So don’t look for a hockey stick, it’s a gradual process where, of course, we will be starting at the lower doses and then increasing them as we move forward. There are different data sources in terms of new starts. So I’m not really sure what your data source is, but I think my data point is lower than yours in terms of number of new starts per week.
Daniel Bohsen: Thank you, Karsten. Thank you, Naresh. And we are ready for the next question please.
Operator: Thank you. Your next question comes from the line of Florent Cespedes from Societe Generale. Please go ahead.
Florent Cespedes: Good afternoon. Thank you very much for taking my questions. Two, please. First one on Wegovy in Europe. Have you started to talk to the payers in Europe as you have already submitted the data to the European authorities and do you believe that you will need to show statistically significant benefit on the cardiovascular best will be presented at AHA next week? And my second question is on Ozempic following the FLOW results. How would you position the product on this population as we already have products available to treat these patients, notably the SGLT2. And it seems that in the trial 15% of the patients are under SGLT2 treatments. So some color on this one would be helpful. Thank you.
Daniel Bohsen: Thank you, Florent. Camilla, maybe, the first one for you in terms of Wegovy outside the US.
Camilla Sylvest: Yes. So in terms of, I believe, the question was whether we need statistical significance. I would just say now we await the presentation at the conference. But in general, there is a great interest in Wegovy and of course also the benefits in SELECT. So we will get back to that. But we have — we do see authorities interested in bringing up the discussion again with us already at this point for reimbursement of Wegovy. And just a reminder, we have reimbursement of Saxenda already in a close to 15 countries around the world and of course here we are talking a step up in treatment.
Daniel Bohsen: Thank you, Camilla. Martin any medical perspectives on FLOW and the population that we potentially could treat.
Martin Holst Lange: Yeah, absolutely maybe just also calling out on SELECT, the study was designed to have the power specifically for the primary endpoint. So assuming statistical significant for the secondary endpoints is to be seen as an upside and not as something to be expected. I just want to call that out, but obviously please tune in on what we can present on November 11th in Philadelphia. Specifically on FLOW, I think there’s a tremendous unmet need in the diabetes space. It’s also very, very clear that not all patients today who suffer from diabetes and chronic kidney disease are on an SGLT2 and on GLP-1 and therefore to have data to suggest that we can actually decrease and again we haven’t seen the data, but we can potentially decrease, the kidney disease deterioration by a substantial number on top of standard of care, including SGLT2 is really, really attractive offering and it will allow more patients in need to get on GLP-1.
